Ibuprofen: From invention to an OTC therapeutic mainstay

International Journal of Clinical Practice

Volumn 67, Issue SUPPL. 178, 2013, Pages 9-20

  Rainsford, K D ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROSTAGLANDIN;

ALLERGIC REACTION; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSMENORRHEA; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEARTBURN; HUMAN; INFLAMMATORY PAIN; INJURY; LOW DRUG DOSE; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PAIN; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STEREOCHEMISTRY; TOOTH PAIN; TREATMENT DURATION; VOMITING;

EID: 84894267752     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12055     Document Type: Review

References (93)

1. Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 2009; 17: 275-342.
2. Rainsford KD. Fifty years since the discovery of ibuprofen. Inflammopharmacology 2011; 19: 293-7.
3. Copeman WCS, ed. Textbook of the Rheumatic Diseases, 3rd edn. Edinburgh & London: E & S Livingstone, 1964.
4. Boyle JA, Buchanan WW. Clinical Rheumatology. Oxford & Edinburgh: Blackwell, 1971.
5. Cuthbert MF. Adverse reactions to non-steroidal anti-rheumatic drugs. Curr Med Res Opin 1974; 2: 600-9.
6. Piper DW, Greig M, Landecker KD, Shinners J, Waller S, Canalese J. Analgesic intake and chronic gastric ulcer. Acute upper gastrointestinal haemorrhage, personality traits and social class. Proc R Soc Med 1977; 70: 11-5.
7. Duggan JM. Gastrointestinal toxicity of minor analgesics. Br J Clin Pharmacol 1980; 10: 407S-10S. (Pubitemid 11214332)
8. Rainsford KD. Aspirin and Related Drugs. London: Taylor & Francis; 2004: 367-554.
9. Rainsford KD. Ibuprofen: A Critical Bibliographic Review. London: Taylor & Francis, 1999: 1-24.
10. Dieppe P, Blake D. Copeman's Textbook of the Rheumatic Diseases, 6th edn. Edinburgh: Churchill Livingstone, 1986: 281-308.
11. Adams SS. The discovery of brufen. Chem Br 1987; 23: 1193-5.
12. Boardman PL, Nuki G, Hart FD. Ibuprofen in the treatment of rheumatoid arthritis and osteo-arthritis. Ann Rheum Dis 1967; 26: 560-1.
13. Kean WF, Buchanan WW, Rainsford KD. Therapeutics of ibuprofen in rheumatic and other chronic and painful diseases. Ibuprofen. A Critical Bibliographic Review. London: Taylor & Francis, 1999: 277-353.
14. Cardoe N. A review of long-term experience with ibuprofen, with special reference to gastric tolerance. Rheum Phys Med 1970; 11: 28-31.
15. Adatia A, Rainsford KD, Kean WF. Osteoarthritis of the knee and hip. Part II: therapy with ibuprofen and a review of clinical trials. J Pharm Pharmacol 2012; 64: 626-36.
16. Thomson M, Anderson M. Studies on the gastrointestinal blood loss during ibuprofen therapy. Rheum Phys Med 1971; 11: 104-8.
17. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
18. Flower R, Gryglewski R, Herbaczyńska-Cedro K, Vane JR. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol 1972; 238: 104-6.
19. Rainsford KD. Inhibitors of Eicosanoids. The Eicosanoids. Chichester: John Wiley & Sons, 2004.
20. Shen TY. The discovery proliferation of non-steroidal anti-inflammatory drugs (NSAIDs). Discoveries in Pharmacology. Vol 2. Haemodynamics, Hormones and Inflammation. Amsterdam: Elsevier, 1984: 523-53.
21. Hersh EV, Moore PA, Ross GL. Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther 2000; 22: 500-48. (Pubitemid 30434308)
22. Rainsford KD. The ever-emerging anti-inflammatories. Have there been any real advances?. J Physiol Paris 2001; 95: 11-9.
23. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release. Arch Intern Med 2005; 165: 171-7.
24. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007; 42: 3-27.
25. Marnett LJ. The COXIB experience: a look in the rearview mirror. Annu Rev Pharmacol Toxicol 2009; 49: 265-90.
26. Treacy L Competing pain relievers: aspirin, acetaminophen, and ibuprofen. http://www.health guidance.org/entry/9825/1/Competing-Pain-Relievers- Aspirin-Acetaminophen-and-Ibuprofen.html (accessed October 2012).
27. Rainsford KD. Ibuprofen: Pharmacology, Therapeutics and Side Effects. Basel & Heidelberg: Springer, 2012. in press.
28. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New Engl J Med 2001; 345: 1809-17.
29. Antman EM, Bennett JS, Daugherty A et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115: 1634-42. (Pubitemid 46648649)
30. Rainsford KD, Kean WF. Are "mega" coxibs and NSAIDs finished in rheumatology. Inflammopharmacology 2012; submitted.
31. Kanabar D. Ibuprofen and asthma in paediatric populations: clinical concern or clinical reality? J R Soc Med 2007; 100: 15-7. (Pubitemid 351204442)
32. Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. Am Fam Physician 2009; 80: 1371-8.
33. Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. Arch Pediatr Adolesc Med 2004; 158: 521-6. (Pubitemid 38720481)
34. Eustace N, O'Hare B. Use of nonsteroidal antiinflammatory drugs in infants. A survey of members of the Association of Paediatric Anaesthetists of Great Britain and Ireland. Paediatr Anaesth 2007; 17: 464-9. (Pubitemid 46633386)
35. Ross NS, Hoppel CL. Partial muscle carnitine palmitoyltransferase- A deficiency. Rhabdomyolysis associated with transiently decreased muscle carnitine content after ibuprofen therapy. J Am Med Assn 1987; 257: 62-5. (Pubitemid 17205273)
36. Ramachandran S, Giles PD, Hartland A. Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment. Br Med J 1997; 314: 1593. (Pubitemid 27229111)
37. Kordish I, Herrmann BL, Lahner H, Schroeder T, Janssen OE, Mann K. Rhabdomyolysis, hyponatremia and fever in a patient with Schmidt's syndrome. Dtsch Med Wochenschr 2003; 128: 1649-52. (Pubitemid 37076055)
38. Lanas A. A review of the gastrointestinal safety data - a gastroenterologist's perspective. Rheumatology (Oxford) 2010; 49: ii3-ii10.
39. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010; 39: 433-64.
40. Lee I, Cryer B. Epidemiology and role of nonsteroidal antiinflammatory drugs in causing gastrointestinal bleeding. Gastrointest Endosc Clin N Am 2011; 21: 597-612.
41. Mallen SR, Essex MN, Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin 2011; 27: 1359-66.
42. Michels SL, Collins J, Reynolds MW, Abramsky S, Paredes-Diaz A, McCarberg B. Over-the-counter ibuprofen and risk of gastrointestinal bleeding complications: a systematic literature review. Curr Med Res Opin 2012; 28: 89-99.
43. [No authors listed]. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs. Prescrire Int 2011; 20: 216- 9.
44. Jüni P, Dieppe P. Older people should NOT be prescribed 'coxibs' in place of conventional NSAIDs. Age Ageing 2004; 33: 100-4. (Pubitemid 38313105)
45. Rainsford KD, Roberts SC, Brown S. Ibuprofen and paracetamol: relative safety in non-prescription dosages. J Pharm Pharmacol 1997; 49: 345-76. (Pubitemid 27207690)
46. Moore N, Charlesworth A, Van Ganse E et al. Risk factors for adverse events in analgesic drug users: results from the PAIN study. Pharmacoepidemiol Drug Saf 2003; 12: 601-10. (Pubitemid 37220647)
47. Adams SS. Non-steroidal anti-inflammatory drugs, plasma half-lives, and adverse reactions. Lancet 1987; 2: 1204-5. (Pubitemid 17156610)
48. Henry D, Drew A, Beuzeville S. Safety and Efficacy of Non-Prescription (OTC) Analgesics and NSAIDs. Dordrecht: Kluwer Academic Publishers, 1998: 19- 45.
49. Bjarnason I, Scarpignato C, Takeuchi K, Rainsford KD. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther 2007; 26: 95-106. (Pubitemid 46889838)
50. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety. Clin Interv Aging 2011; 6: 125-31.
51. Wang X, Tian HJ, Yang HK, Wanyan P, Peng YJ. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 2011; 23: 876-80.
52. Bjarnason I. Gastro-intestinal safety of NSAIDs and over-the-counter analgesics. Int J Clin Pract 2013; 67 (Suppl. 178): 37-42.
53. Dutch MJ. Nurofen Plus misuse: an emerging cause of perforated gastric ulcer. Med J Aust 2008; 188: 56-7.
54. Robinson GM, Robinson S, McCarthy P, Cameron C. Misuse of over-the-counter codeine-containing analgesics: dependence and other adverse effects. N Z Med J 2010; 123: 59-64.
55. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J et al. Duration of treatment with nonsteroidal antiinflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123: 2226-35.
56. Fosbøl EL, Køber L, Torp-Pedersen C, Gislason GH. Cardiovascular safety of non-steroidal antiinflammatory drugs among healthy individuals. Expert Opin Drug Saf 2010; 9: 893-903.
57. Padol IT, Hunt RH. Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence- based interpretation. Rheumatology (Oxford) 2010; 49: 837-43.
58. Rainsford KD. Cardiovascular adverse reactions from NSAIDs are more than COX-2 inhibition alone. Rheumatology (Oxford) 2010; 49: 834-6.
59. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six nonsteroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008; 101: 1060-3.
60. Schuijt MP, Huntjens-Fleuren HW, de Metz M, Vollaard EJ. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol 2009; 157: 931-4.
61. Awa K, Satoh H, Hori S, Sawada Y. Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic / pharmacodynamic model. J Clin Pharm Ther 2012; 132: 135-44.
62. Food & Drug Administration. Information for healthcare professionals: Concomitant use of ibuprofen and aspirin, new information [9 / 2006]. http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm 125222.htm (accessed October 2012).
63. Spector WG, Willoughby DA. The inflammatory response. Bacteriol Rev 1963; 27: 117-54.
64. Wiloughby DA, Spector WG. The Pharmacology of Inflammation. London: Hodder & Stoughton, 1968.
65. Whitehouse MW. Some biochemical and pharmacological properties of anti-inflammatory drugs. Fortschr Arzneimittelforsch 1965; 8: 321-429.
66. Samuelsson B, Paoletti R, Granstrom E, Folco G, Ramwell PW, Nicosia S, eds. Prostaglandins and related compounds. Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 1-554.
67. Rainsford KD. Ibuprofen. A Critical Bibliographic Review. London: Taylor & Francis, 1999: 143-275.
68. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th edn. Edinburgh: Churchill Livingstone, 2003: 7-50. 91-105.
69. Villanueva M, Heckenberger R, Strobach H, Palmér M, Schrör K. Equipotent inhibition by R(-)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro. Br J Pharmacol 1993; 35: 235-42. (Pubitemid 23074046)
70. Ballou LR, Botting RM, Goorha S, Zhang J, Vane JR. Nociception in cyclooxygenase isoenzymes deficient mice. Proc Nat Acad Sci USA 2000; 97: 10272-6.
71. Martínez RV, Reval MID, Campos MD, Terrón JA, Domínguez R, López-Muñoz FJ. Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain. J Pharm Pharmacol 2002; 54: 405-12. (Pubitemid 34232341)
72. Zhu X, Conklin D, Eisenach JC. Cyclooxygenase-1 in the spinal cord plays an important role in postoperative pain. Pain 2003; 104: 15-23. (Pubitemid 36835870)
73. Zhu X, Conklin D, Eisenach JC. Perioperative inhibition of cyclooxygenase-1 in the spinal cord reduces post-operative pain. Anesth Anal 2005; 100: 1390-3. (Pubitemid 40577392)
74. Perrone MG, Scilimati A, Simone L, Vitale P. Selective COX-1 inhibition: a therapeutic target to be reconsidered. Curr Med Chem 2010; 17: 3769-805.
75. Vanegas H, Schaible H-G. Prostaglandins and cyclooxygenases in the spinal cord. Prog Neurobiol 2001; 64: 327-63.
76. Rainsford KD. Ibuprofen: Pharmacology, Therapeutics and Side-Effects. Basel: Springer Basel (AG), 2012.
77. Gould HJ 3rd, England JD, Soignier RD et al. Ibuprofen blocks changes in Na v 1.7 and 1.8 sodium channels associated with complete Freund's adjuvant- induced inflammation in rat. J Pain 2004; 5: 270-80. (Pubitemid 38859681)
78. Huang ZJ, Hsu E, Li HC, Rosner AL, Rupert RL, Song XJ. Topical application of compound Ibuprofen suppresses pain by inhibiting sensory neuron hyperexcitability and neuroinflammation in a rat model of intervertebral foramen inflammation. J Pain 2011; 12: 141-52.
79. Jones NG, Slater R, Cadiou H, McNaughton P, McMahon SB. Acid-induced pain and its modulation in humans. J Neurosci 2004; 24: 10974-9. (Pubitemid 39602408)
80. Southall MD, Michael RL, Vasko MR. Intrathecal NSAIDS attenuate inflammation-induced neuropeptide release from rat spinal cord slices. Pain 1998; 78: 39-48. (Pubitemid 28451527)
81. Fowler CJ, Naidu PS, Lichtman A, Onnis V. The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br J Pharmacol 2009; 156: 412-9.
82. Fowler CJ, Björklund E, Lichtman AH, Naidu PS, Congiu C, Onnis V. Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. J Enzyme Inhib Med Chem 2012. Jan 6. [Epub ahead of print].
83. Blain H, Boileau C, Lapicque F et al. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol 2002; 53: 255-65. (Pubitemid 34228907)
84. Birk JW, Myers M. A fixed dose combination of ibuprofen and famotidine. Expert Opin Investig Drugs 2009; 18: 1385-91.
85. Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS. Double-blind randomized trials of singletablet ibuprofen / high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012; 107: 379-86.
86. Lichtenberger LM, Barron M, Marathi U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today (Barc) 2009; 45: 877-90.
87. Lanza FL, Marathi UK, Anand BS, Lichtenberger LM. Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment Pharmacol Ther 2008; 28: 431-42. (Pubitemid 352033288)
88. Harris RE ed. COX-2 Blockade in Cancer Prevention and Therapy. Totawa, New Jersey: Humana Press; 2002.
89. Rostom A, Dube C, Lewin G. [internet]. Use of Aspirin and NSAIDs to Prevent ColorectalCancer. Rockville (MD): Agency for Healthcare Research and Quality (US), 2007. http://www.ncbi.nlm.nih.gov/books/NBK33464/(accessed October 2012).
90. Johnson CC, Hayes RB, Schoen RE, Gunter MJ, Huang WY; PLCO Trial Team. Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial. Am J Gastroenterol 2010; 105: 2646-55.
91. Mahmud SM, Franco EL, Turner D et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS ONE 2011; 6: e16412.
92. Brasky TM, Bonner MR, Moysich KB et al. Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat 2011; 126: 157-65.
93. Baris D, Karagas MR, Koutros S et al. Nonsteroidal anti-inflammatory drugs and other analgesic use and bladder cancer in northern New England. Int J Cancer 2012. Apr 14. [Epub ahead of print].